Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 9/20 | 0.36 |
| ▸ | CLK1 | P49759 | 9/20 | 0.36 |
| ▸ | CLK2 | P49760 | 9/20 | 0.36 |
| ▸ | CLK3 | P49761 | 9/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 9/20 | 0.36 |
| ▸ | DYRK4 | Q9NR20 | 9/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 9/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 8/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.36 |
| ▸ | GSK3B | P49841 | 8/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6399280 | 1.00 | MMP2 (0.38) | MMP2MMP9NAMPTIKBKBDYRK3 | |
| SCHEMBL6399017 | 0.86 | MMP2 (0.38) | MMP2MMP9DYRK1BGSK3BCDK5 | |
| SCHEMBL6399012 | 0.86 | MMP2 (0.38) | MMP2MMP9DYRK1BGSK3BCDK5 | |
| SCHEMBL6400319 | 0.79 | MMP2 (0.39) | MMP2MMP9DYRK1BGSK3BCDK5 | |
| SCHEMBL6399715 | 0.79 | MMP2 (0.39) | MMP2MMP9DYRK1BGSK3BCDK5 | |
| SCHEMBL6403857 | 0.79 | ACP1 (0.40) | MMP2MMP9RAB9A | |
| SCHEMBL6403864 | 0.79 | ACP1 (0.40) | MMP2MMP9RAB9A | |
| SCHEMBL6401008 | 0.78 | MMP2 (0.45) | MMP2MMP9DYRK1BGSK3BCDK5 | |
| SCHEMBL6401013 | 0.78 | MMP2 (0.45) | MMP2MMP9DYRK1BGSK3BCDK5 | |
| SCHEMBL6400665 | 0.78 | MMP2 (0.40) | MMP2MMP9DYRK1BGSK3BCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | claimed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | claimed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | claimed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | claimed |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | MMP2 2931/4885MMP9 3613/4885NAMPT 3587/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | MMP2 2846/4885MMP9 3775/4885NAMPT 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.